Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lilly Halts Trials Of PPAR Alpha Agonist After Preclinical Safety Signal

This article was originally published in The Pink Sheet Daily

Executive Summary

Phase II clinical trials of the atherosclerosis treatment candidate LY674 were halted after a primate study showed fatty liver deposits.

You may also be interested in...



Roche Drops Aleglitazar In Another Cardiology/Metabolics Setback

Development of dual PPAR agonist aleglitazar terminated due to fractures, renal impairment and heart failure reported in the AleCardio study, leaving another hole in Roche’s cardiovascular/metabolic pipeline.

Roche Drops Aleglitazar In Another Cardiology/Metabolics Setback

Development of dual PPAR agonist aleglitazar terminated due to fractures, renal impairment and heart failure reported in the AleCardio study, leaving another hole in Roche’s cardiovascular/metabolic pipeline.

Bristol Joins The Ranks: Firm Bags Pargluva Development

Merck, AstraZeneca and Roche have already stepped out of the dual PPAR development arena.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS063228

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel